Skip to content

BillionToOne, Inc. BLLN Proceeds From Warrant Exercises

Proceeds From Warrant Exercises at other companies

ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$53.54M
Summit Therapeutics logo
Summit TherapeuticsSMMT
$0-100%

Other financials

Income statement

See full
Revenue$108.4M+83.8%
Gross profit$79.1M+108%
Operating income$17.8M+870%
Net income$18.0M+551%
EPS (diluted)$0.34+187%

Balance sheet

See full
Cash & equivalents$537.5M+181%
Total debt$144.2M
Total equity$505.6M+300%
Total assets$700.7M

Cash flow

See full
Operating cash flow$15.4M+488%
CapEx$4.5M+90.5%
Free cash flow$11.0M+3,842%

Valuation

See full
Market cap$4.8B

Profitability

See full
Gross margin70.4%
Operating margin-96.9%
Net margin8.4%
FCF margin-83.4%

Returns & leverage

See full
Debt / equity0.3×
Current ratio10.9×

Where this comes from

Reported directly by BillionToOne, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromWarrantExercises.

The official record: BillionToOne, Inc. ’s 10-K, filed March 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about BillionToOne, Inc. 's proceeds from warrant exercises.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BillionToOne, Inc. 's proceeds from warrant exercises?
BillionToOne, Inc. (BLLN) reported proceeds from warrant exercises of $6.25K in Q4 2025.
What does proceeds from warrant exercises mean?
Represents the cash inflow generated when holders of stock warrants exercise their rights to purchase company shares. This serves as a source of non-dilutive or secondary capital that strengthens the balance sheet. It reflects investor confidence and the conversion of financial instruments into equity.